|
NL188581C
(nl)
*
|
1974-07-15 |
1992-08-03 |
Akzo Nv |
Werkwijze voor het bereiden van 11beta-hydroxy-18-alkylestraanverbindingen.
|
|
ZA763131B
(en)
*
|
1975-05-27 |
1978-01-25 |
Syntex Inc |
Use of flunisolide to treat respiratory diseases
|
|
SE8008524L
(sv)
*
|
1980-12-04 |
1982-06-05 |
Draco Ab |
4-pregnen-derivat, ett forfarande for deras framstellning, beredning och metod for behandling av inflammatoriska tillstand
|
|
IT1196142B
(it)
*
|
1984-06-11 |
1988-11-10 |
Sicor Spa |
Procedimento per la preparazione di 16,17-acetali di derivati pregnanici e nuovi composti ottenuti
|
|
SE8604059D0
(sv)
*
|
1986-09-25 |
1986-09-25 |
Astra Pharma Prod |
A method of controlling the epimeric distribution in the preparation of 16,17-acetals of pregnane derivatives
|
|
GR1001529B
(el)
*
|
1990-09-07 |
1994-03-31 |
Elmuquimica Farm Sl |
Μέ?οδος για την λήψη νέων 21-εστέρων της 16-17-ακετάλης της πρ να-1,4-διενο-3,20-διόνης.
|
|
SE9100341D0
(sv)
*
|
1991-02-04 |
1991-02-04 |
Astra Ab |
Novel steroids
|
|
WO1994015947A1
(en)
*
|
1993-01-08 |
1994-07-21 |
Astra Aktiebolag |
Novel colon- or ileum-specific steroid derivatives
|
|
DE19635498A1
(de)
*
|
1996-09-03 |
1998-03-26 |
Byk Gulden Lomberg Chem Fab |
Verfahren zur Epimerenanreicherung
|
|
IT1291288B1
(it)
|
1997-04-30 |
1999-01-07 |
Farmabios Srl |
Processo per la preparazione di 16,17 acetali di derivati pregnanici con controllo della distribuzione epimerica al c-22.
|
|
US6266556B1
(en)
|
1998-04-27 |
2001-07-24 |
Beth Israel Deaconess Medical Center, Inc. |
Method and apparatus for recording an electroencephalogram during transcranial magnetic stimulation
|
|
IL144900A
(en)
|
2001-08-14 |
2013-12-31 |
Neurim Pharma 1991 |
Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs
|
|
RU2387646C2
(ru)
*
|
2003-08-29 |
2010-04-27 |
Рэнбакси Лабораториз Лимитед |
Ингибиторы фосфодиэстеразы типа-iv
|
|
EP1694655A2
(en)
*
|
2003-11-26 |
2006-08-30 |
Ranbaxy Laboratories Limited |
Phosphodiesterase inhibitors
|
|
AU2005233569B2
(en)
|
2004-04-09 |
2010-08-19 |
Merck Sharp & Dohme Corp. |
Inhibitors of Akt activity
|
|
WO2006123182A2
(en)
|
2005-05-17 |
2006-11-23 |
Merck Sharp & Dohme Limited |
Cyclohexyl sulphones for treatment of cancer
|
|
EP1934219A1
(en)
|
2005-09-16 |
2008-06-25 |
Ranbaxy Laboratories Limited |
Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
|
|
CA2626628A1
(en)
*
|
2005-10-19 |
2007-04-26 |
Ranbaxy Laboratories Limited |
Compositions of phosphodiesterase type iv inhibitors
|
|
WO2007045979A1
(en)
|
2005-10-19 |
2007-04-26 |
Ranbaxy Laboratories Limited |
Pharmaceutical compositions of muscarinic receptor antagonists
|
|
US20100029728A1
(en)
*
|
2006-09-22 |
2010-02-04 |
Ranbaxy Laboratories Limited |
Phosphodiesterase inhibitors
|
|
AU2007298549A1
(en)
*
|
2006-09-22 |
2008-03-27 |
Ranbaxy Laboratories Limited |
Inhibitors of phosphodiesterase type-IV
|
|
US20110218176A1
(en)
|
2006-11-01 |
2011-09-08 |
Barbara Brooke Jennings-Spring |
Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
|
|
US9408816B2
(en)
|
2006-12-26 |
2016-08-09 |
Pharmacyclics Llc |
Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy
|
|
GEP20115337B
(en)
|
2007-01-10 |
2011-11-25 |
St Di Ricerche Di Biologia Molecolare P Angeletti Spa |
Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
|
|
US20080207659A1
(en)
*
|
2007-02-15 |
2008-08-28 |
Asit Kumar Chakraborti |
Inhibitors of phosphodiesterase type 4
|
|
EP2124943A1
(en)
*
|
2007-03-14 |
2009-12-02 |
Ranbaxy Laboratories Limited |
Pyrazolo [3, 4-b]pyridine derivatives as phosphodiesterase inhibitors
|
|
EP2124944B1
(en)
*
|
2007-03-14 |
2012-02-15 |
Ranbaxy Laboratories Limited |
Pyrazolo[3,4-b]pyridine derivatives as phosphodiesterase inhibitors
|
|
AU2008269154B2
(en)
|
2007-06-27 |
2014-06-12 |
Merck Sharp & Dohme Llc |
4-carboxybenzylamino derivatives as histone deacetylase inhibitors
|
|
ITMI20080645A1
(it)
|
2008-04-11 |
2009-10-12 |
Ind Chimica Srl |
Procedimento per la preparazione di budesonide
|
|
EP2111861A1
(en)
|
2008-04-21 |
2009-10-28 |
Ranbaxy Laboratories Limited |
Compositions of phosphodiesterase type IV inhibitors
|
|
GB0900484D0
(en)
|
2009-01-13 |
2009-02-11 |
Angeletti P Ist Richerche Bio |
Therapeutic agent
|
|
WO2010114780A1
(en)
|
2009-04-01 |
2010-10-07 |
Merck Sharp & Dohme Corp. |
Inhibitors of akt activity
|
|
US8603521B2
(en)
|
2009-04-17 |
2013-12-10 |
Pharmacyclics, Inc. |
Formulations of histone deacetylase inhibitor and uses thereof
|
|
JP2013504524A
(ja)
*
|
2009-09-11 |
2013-02-07 |
シエシー ファルマセウティチィ ソシエタ ペル アチオニ |
イソオキサゾリジン誘導体
|
|
GB0916608D0
(en)
|
2009-09-22 |
2009-11-04 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
|
MY174452A
(en)
|
2009-10-14 |
2020-04-19 |
Schering Corp |
Substituted piperidines that increase p53 activity and the uses thereof
|
|
EP2534145A4
(en)
|
2010-02-08 |
2013-09-11 |
Kinagen Inc |
THERAPEUTIC METHODS AND COMPOSITIONS INVOLVING THE INHIBITION OF ALLOSTERIC KINASE
|
|
US8999957B2
(en)
|
2010-06-24 |
2015-04-07 |
Merck Sharp & Dohme Corp. |
Heterocyclic compounds as ERK inhibitors
|
|
US8518907B2
(en)
|
2010-08-02 |
2013-08-27 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
|
|
EP3587574B1
(en)
|
2010-08-17 |
2022-03-16 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina)
|
|
US8883801B2
(en)
|
2010-08-23 |
2014-11-11 |
Merck Sharp & Dohme Corp. |
Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
|
|
US8946216B2
(en)
|
2010-09-01 |
2015-02-03 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as ERK inhibitors
|
|
US9242981B2
(en)
|
2010-09-16 |
2016-01-26 |
Merck Sharp & Dohme Corp. |
Fused pyrazole derivatives as novel ERK inhibitors
|
|
US9260471B2
(en)
|
2010-10-29 |
2016-02-16 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
|
|
EP2654748B1
(en)
|
2010-12-21 |
2016-07-27 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as erk inhibitors
|
|
CA2833009A1
(en)
|
2011-04-21 |
2012-10-26 |
Merck Sharp & Dohme Corp. |
Insulin-like growth factor-1 receptor inhibitors
|
|
KR101892788B1
(ko)
|
2011-09-13 |
2018-08-28 |
파마싸이클릭스 엘엘씨 |
벤다무스틴과 조합된 히스톤 디아세틸라제 억제제의 제제 및 그의 용도
|
|
US9023865B2
(en)
|
2011-10-27 |
2015-05-05 |
Merck Sharp & Dohme Corp. |
Compounds that are ERK inhibitors
|
|
EP3919620A1
(en)
|
2012-05-02 |
2021-12-08 |
Sirna Therapeutics, Inc. |
Short interfering nucleic acid (sina) compositions
|
|
US9018380B2
(en)
|
2012-08-24 |
2015-04-28 |
Boar of Regents, The University of Texas System |
Heterocyclic modulators of HIF activity for treatment of disease
|
|
US9155747B2
(en)
*
|
2012-09-13 |
2015-10-13 |
Chiesi Farmaceutici S.P.A. |
Isoxazolidine derivatives
|
|
JP6280554B2
(ja)
|
2012-09-28 |
2018-02-14 |
メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. |
Erk阻害剤である新規化合物
|
|
DK2925888T3
(en)
|
2012-11-28 |
2017-12-18 |
Merck Sharp & Dohme |
COMPOSITIONS AND METHODS OF CANCER TREATMENT
|
|
AR094116A1
(es)
|
2012-12-20 |
2015-07-08 |
Merck Sharp & Dohme |
Imidazopiridinas sustituidas como inhibidores de hdm2
|
|
WO2014120748A1
(en)
|
2013-01-30 |
2014-08-07 |
Merck Sharp & Dohme Corp. |
2,6,7,8 substituted purines as hdm2 inhibitors
|
|
US20160194368A1
(en)
|
2013-09-03 |
2016-07-07 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
|
US11066396B2
(en)
|
2016-06-23 |
2021-07-20 |
Merck Sharp & Dohme Corp. |
3-aryl- heteroaryl substituted 5-trifluoromethyl oxadiazoles as histonedeacetylase 6 (HDAC6) inhibitors
|
|
EP3525785B1
(en)
|
2016-10-12 |
2025-08-27 |
Merck Sharp & Dohme LLC |
Kdm5 inhibitors
|
|
AU2017359043B2
(en)
|
2016-11-08 |
2022-06-16 |
Regeneron Pharmaceuticals, Inc. |
Steroids and protein-conjugates thereof
|
|
KR20200007905A
(ko)
|
2017-05-18 |
2020-01-22 |
리제너론 파마슈티칼스 인코포레이티드 |
사이클로덱스트린 단백질 약물 접합체
|
|
CA3080857A1
(en)
|
2017-11-07 |
2019-05-16 |
Regeneron Pharmaceuticals, Inc. |
Hydrophilic linkers for antibody drug conjugates
|
|
EP3706747B1
(en)
|
2017-11-08 |
2025-09-03 |
Merck Sharp & Dohme LLC |
Prmt5 inhibitors
|
|
EA202091672A1
(ru)
|
2018-01-08 |
2021-02-01 |
Регенерон Фармасьютикалз, Инк. |
Стероиды и их антитело-конъюгаты
|
|
WO2019217591A1
(en)
|
2018-05-09 |
2019-11-14 |
Regeneron Pharmaceuticals, Inc. |
Anti-msr1 antibodies and methods of use thereof
|
|
EP3833355A4
(en)
|
2018-08-07 |
2022-05-11 |
Merck Sharp & Dohme Corp. |
PRMT5 INHIBITORS
|
|
WO2020033284A1
(en)
|
2018-08-07 |
2020-02-13 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
|
US11993602B2
(en)
|
2018-08-07 |
2024-05-28 |
Merck Sharp & Dohme Llc |
PRMT5 inhibitors
|
|
AU2020408148B2
(en)
|
2019-12-17 |
2025-04-24 |
Merck Sharp & Dohme Llc |
PRMT5 inhibitors
|
|
US20230108114A1
(en)
|
2019-12-17 |
2023-04-06 |
Merck Sharp & Dohme Llc |
Prmt5 inhibitors
|
|
WO2021126729A1
(en)
|
2019-12-17 |
2021-06-24 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
|
CN120225528A
(zh)
|
2022-09-02 |
2025-06-27 |
默沙东有限责任公司 |
依喜替康衍生的拓扑异构酶-1抑制剂药物组合物及其用途
|
|
CR20250146A
(es)
|
2022-10-25 |
2025-05-26 |
Merck Sharp & Dohme Llc |
Enlazadores-cargas útiles de adc derivados de exatecán, composiciones farmacéuticas, y usos de los mismos
|
|
CN120359051A
(zh)
|
2022-12-14 |
2025-07-22 |
默沙东有限责任公司 |
奥瑞他汀接头-载荷、药物组合物及其用途
|